YD Bio Ltd

# YD Bio Ltd (YDES)

YD Bio Limited is a biopharmaceutical company headquartered in Taipei, Taiwan that operates across two primary therapeutic areas: blood-based cancer detection and regenerative medicine. The company develops liquid biopsy technologies for early cancer detection alongside stem cell- and exosome-based therapeutics targeting diseases with limited treatment options. The company is incorporated in the Cayman Islands and trades on the Nasdaq.

The company's pipeline spans oncology diagnostics and cell therapy platforms. Its blood-based cancer detection program focuses on enabling non-invasive screening through circulating biomarker analysis, while its regenerative medicine initiatives leverage stem cell and exosome technologies to address multiple disease indications. The organization maintains research and development operations in Asia, supporting its drug development efforts.

Specific information regarding employee count, total revenue figures, and geographic distribution of commercial operations is not available in current public disclosures. With a market capitalization of approximately $0.6 billion, YD Bio operates at the scale of an early-stage biopharmaceutical developer, indicating that the company likely remains in clinical development or early commercialization phases rather than generating significant product revenues.